Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.630
+0.115 (7.59%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Neumora Therapeutics Employees
Neumora Therapeutics had 63 employees as of June 30, 2026. The number of employees decreased by 33 or -34.38% compared to the same quarter last year.
Employees
63
Change
-33
Growth
-34.38%
Revenue / Employee
n/a
Profits / Employee
-$3,376,905
Market Cap
306.27M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 63 | -33 | -34.38% |
| Mar 31, 2026 | 92 | -11 | -10.68% |
| Dec 31, 2025 | 96 | -14 | -12.73% |
| Sep 30, 2025 | 95 | -14 | -12.84% |
| Jun 30, 2025 | 96 | -12 | -11.11% |
| Mar 31, 2025 | 103 | -17 | -14.17% |
| Dec 31, 2024 | 110 | -14 | -11.29% |
| Sep 30, 2024 | 109 | -1 | -0.91% |
| Jun 30, 2024 | 108 | -2 | -1.82% |
| Mar 31, 2024 | 120 | 12 | 11.11% |
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Jun 30, 2023 | 110 | 16 | 17.02% |
| Mar 31, 2023 | 108 | 14 | 14.89% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Mar 31, 2022 | 94 | 41 | 77.36% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Bicycle Therapeutics | 288 |
| Invivyd | 122 |
| AC Immune | 122 |
| Orchestra BioMed Holdings | 86 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
| Vicore Pharma Holding AB | 40 |
NMRA News
- 5 days ago - Neumora CEO transition not a surprise, says H.C. Wainwright - TheFly
- 6 days ago - Neumora Therapeutics reports Q2 EPS (23c), consensus (24c) - TheFly
- 6 days ago - Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed - TheFly
- 8 days ago - Neumora Therapeutics Slides: Company presentation - Filings
- 8 days ago - Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 8 days ago - Neumora Therapeutics Earnings release: Q2 2026 - Filings
- 8 days ago - Neumora Therapeutics Quarterly report: Q2 2026 - Filings
- 26 days ago - Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study - TheFly